ACADIA Pharmaceuticals Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
654
- Stock Symbol
-
ACAD
- Investments
-
2
- Share Price
-
$14.73
- (As of Friday Closing)
ACADIA Pharmaceuticals General Information
Description
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Contact Information
Website
www.acadia.comCorporate Office
- 12830 El Camino Real
- Suite 400
- San Diego, CA 92130
- United States
Corporate Office
- 12830 El Camino Real
- Suite 400
- San Diego, CA 92130
- United States
ACADIA Pharmaceuticals Stock Performance
As of 25-Apr-2025, ACADIA Pharmaceuticals’s stock price is $14.73. Its current market cap is $2.46B with 167M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $14.73 | $14.83 | $13.40 - $20.68 | $2.46B | 167M | 1.68M | $1.37 |
ACADIA Pharmaceuticals Financials Summary
As of 31-Dec-2024, ACADIA Pharmaceuticals has a trailing 12-month revenue of $958M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 2,537,331 | 2,537,331 | 4,851,702 | 2,204,362 |
| Revenue | 957,797 | 957,797 | 726,437 | 517,235 |
| EBITDA | 248,500 | 248,500 | (62,718) | (218,028) |
| Net Income | 226,451 | 226,451 | (61,286) | (215,975) |
| Total Assets | 1,187,756 | 1,187,756 | 748,956 | 587,812 |
| Total Debt | 51,995 | 51,995 | 57,205 | 62,000 |
ACADIA Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ACADIA Pharmaceuticals Comparisons
Industry
Financing
Details
ACADIA Pharmaceuticals Competitors (73)
One of ACADIA Pharmaceuticals’s 73 competitors is Catalyst Pharmaceuticals, a Corporation company based in Coral Gables, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals | Corporation | Coral Gables, FL | ||||
| Axsome Therapeutics | Corporation | New York, NY | ||||
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Krystal Biotech | Formerly VC-backed | Pittsburgh, PA | ||||
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA |
ACADIA Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ACADIA Pharmaceuticals Patents
ACADIA Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202209195-D0 | Modulators of g protein-coupled receptor 88 | Inactive | 22-Jun-2022 | ||
| GB-202209193-D0 | Modulators of g protein-coupled receptor 88 | Inactive | 22-Jun-2022 | ||
| AU-2023287668-A1 | Modulators of g protein-coupled receptor 88 | Pending | 22-Jun-2022 | ||
| AU-2023289121-A1 | Modulators of g protein-coupled receptor 88 | Pending | 22-Jun-2022 | ||
| US-20230023114-A1 | Crystalline forms of trofinetide | Active | 12-Jul-2021 | C07D207/16 |
ACADIA Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ACADIA Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ACADIA Pharmaceuticals Investments & Acquisitions (2)
ACADIA Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Neuren (Global Rights in NNZ-2591 in Rett syndrome and Fragile X syndrome) for . The deal was made on 13-Jul-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neuren (Global Rights in NNZ-2591 in Rett syndrome and Fragile X syndrome) | 13-Jul-2023 | Corporate Asset Purchase | Buildings and Property | ||
| CerSci | 01-Aug-2020 | Merger/Acquisition | Biotechnology |
ACADIA Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated March, 12, 2025
30.62 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
ACADIA Pharmaceuticals FAQs
-
When was ACADIA Pharmaceuticals founded?
ACADIA Pharmaceuticals was founded in 1993.
-
Where is ACADIA Pharmaceuticals headquartered?
ACADIA Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals has 654 total employees.
-
What industry is ACADIA Pharmaceuticals in?
ACADIA Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is ACADIA Pharmaceuticals a private or public company?
ACADIA Pharmaceuticals is a Public company.
-
What is ACADIA Pharmaceuticals’s stock symbol?
The ticker symbol for ACADIA Pharmaceuticals is ACAD.
-
What is the current stock price of ACADIA Pharmaceuticals?
As of 25-Apr-2025 the stock price of ACADIA Pharmaceuticals is $14.73.
-
What is the current market cap of ACADIA Pharmaceuticals?
The current market capitalization of ACADIA Pharmaceuticals is $2.46B.
-
What is ACADIA Pharmaceuticals’s current revenue?
The trailing twelve month revenue for ACADIA Pharmaceuticals is $958M.
-
Who are ACADIA Pharmaceuticals’s competitors?
Catalyst Pharmaceuticals, Axsome Therapeutics, SAGE Therapeutics, Krystal Biotech, and Arrowhead Pharmaceuticals are some of the 73 competitors of ACADIA Pharmaceuticals.
-
What is ACADIA Pharmaceuticals’s annual earnings per share (EPS)?
ACADIA Pharmaceuticals’s EPS for 12 months was $1.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
